ARTICLE | Company News
Actelion sales and marketing update
October 29, 2012 7:00 AM UTC
Actelion disclosed in its 3Q12 earnings that in October it launched a second-generation formulation of Veletri epoprostenol in the U.S. to treat pulmonary arterial hypertension (PAH) to improve exerc...